Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate
Cancer Immunology, Immunotherapy · 20.11.2026
DOI: 10.1007/s00262-026-04648-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 20.11.2026. Verfasst von Nanna Skeltved und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEYE foundation, Danmarks Frie Forskningsfond, Novo Nordisk Fonden.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- NEYE foundation
- Danmarks Frie Forskningsfond
- Novo Nordisk Fonden
- Innovationsfonden
- Kræftens Bekæmpelse
- Copenhagen University
Zitieren
APA
Skeltved, N., Martin-Salazar, A., Kolz, H. O., Lopez-Perez, M., Vidal-Calvo, E. E., Choudhary, S., Skov, S., Salanti, A., & Dagil, R. (2026). Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04648-w
Vancouver
Skeltved N, Martin-Salazar A, Kolz HO, Lopez-Perez M, Vidal-Calvo EE, Choudhary S, et al. Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04648-w
BibTeX
@article{Skeltved2026,
author = {Skeltved, Nanna and Martin-Salazar, Anne and Kolz, Henri Oskar and Lopez-Perez, Mary and Vidal-Calvo, Elena Ethel and Choudhary, Swati and Skov, Søren and Salanti, Ali and Dagil, Robert},
title = {Enhanced cytotoxic effect of a glycoengineered monoclonal antibody targeting oncofetal chondroitin sulfate},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04648-w}
}
EUVIMED